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Key messages
What is already known about this subject?
 ► Seasonal influenza vaccination is recommended for 
patients who undergo biological therapy.
 ► Secukinumab does not affect the immune response 
to the influenza vaccine in healthy volunteers.
What does this study add?
 ► Secukinumab does not impair the immune response 
to the influenza vaccine in patients.
How might this impact on clinical practice?
 ► physicians should be concerned about their patients 
on secukinumab seasonal influenza immunisation.
AbstrAct
Objective to evaluate whether immunological response 
to influenza vaccination is impaired in patients who are 
receiving secukinumab.
Patients and methods Subjects suffering from psoriatic 
arthritis or ankylosing spondylitis who were receiving 
treatment with secukinumab and healthy volunteers were 
included.
All participants received seasonal inactivated trivalent 
influenza vaccine recommended by the Who in the 
2017–2018 northern hemisphere influenza season, which 
contained an A/Michigan/45/2015 (h1N1)pdm09-like virus, 
an A/hong Kong/4801/2014 (h3N2)-like virus and a B/
Brisbane/60/2008-like virus.
haemagglutination inhibition was used to evaluate basal 
antibody (Ab) titres against the three influenza vaccine 
virus strains just before vaccination and at least 4 weeks 
after the vaccine administration. response to vaccine was 
considered as >4-fold increases in Ab titre.
Results thirty subjects, 17 patients and 13 healthy 
controls, with a follow-up duration of 33±8 days, were 
analysed. there were no demographic differences between 
groups. patients and controls achieved a median of 4.6-
fold and 4.0-fold increases, respectively, for anti h1N1 
and almost 4.0 (3.7) for patients and 5.3 for controls for 
anti-B Ab. Both groups presented a poor response against 
h3N2, with <1.5-fold increase. Seroconversion rates were 
similar in both groups. Secukinumab did not influence the 
response to the influenza vaccine (relative risk: 1.09 (95% 
CI 0.58 to 2.07) for h1N1, rr: 1.53 (95% CI 0.15 to 15.0) 
for h3N2 and rr: 0.72 (95% CI 0.32 to 1.83) for B strain).
Conclusion In our study, secukinumab has no effect on 
the immunogenic response to the influenza vaccine.
We present a pilot study designed in order to 
acertain if secukinumab impairs the immu-
nogenic response to the influenza vaccine in 
patients with inflammatory arthropathies.
Secukinumab is a fully human anti-inter-
leukin-17A IgG1κ monoclonal antibody (Ab) 
approved for the treatment of psoriasis, psori-
atic arthritis (PsA) and ankylosing spondylitis 
(AS).
Secukinumab has a good safety profile, 
with infection rates similar to etanercept and 
consisting mainly of non-serious nasopharyn-
gitis and upper respiratory tract infections.1
Patients with autoimmune inflammatory 
rheumatic disease (AIIRD) have a higher 
risk of infections than healthy people. There 
are no specific immunisation recommenda-
tions for patients on secukinumab, but taking 
into account they suffer an AIIRD, we follow 
the vaccination guidelines established for 
this population that includes annual influ-
enza vaccination.2 We designed a pilot study 
in order to assess the efficacy of influenza 
vaccine in patients with arthropathies who 
were on treatment with secukinumab.
After the approval of the local ethics 
committees, we enrolled 17 patients suffering 
from PsA or AS and 13 controls, each of whom 
provided a signed written informed consent. 
There were no demographic differences 
between groups. Patients had been receiving 
secukinumab during 8.9±5.8 months. Ten 
patients (58.82%) were also receiving 
concomitant treatment with synthetic 
disease-modifying antirheumatic drugs, five 
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Table 1 Geometric means HI titres against each of the three virus strains before vaccination and at least 4 weeks later
H1N1 
baseline H1N1 final
H3N2 
baseline H3N2 final B baseline B final
Patients on secukinumab, n=17 60 276 65 91 20 74
Healthy controls, n=13 107 428 85 86 32 171
Table 2 Responders against each of the three virus strains
Patients on 
secukinumab, 
n=17 (%)
Healthy 
controls, 
n=13 (%) P value
H1N1 10 (58.82) 7 (53.85) 0.999
H3N2 2 (11.69) 1 (7.69) 1.011
B 6 (35.29) 6 (46.15) 0.821
of them were on leflunomide, four on methotrexate and 
one on sulfasalazine.
All participants received seasonal inactivated triva-
lent influenza vaccine recommended by the WHO in 
the 2017–2018 Northern hemisphere influenza season, 
which contained an A/Michigan/45/2015 (H1N1)
pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-
like virus and a B/Brisbane/60/2008-like virus. Blood 
samples were taken just before vaccination and 33±8 days 
afterwards, and the haemagglutination inhibition test 
was used to evaluate Ab titres against the three vaccine 
virus strains. Participants with >4-fold increases in the Ab 
titre were considered responders.
Patients and controls achieved a median of 4.6-fold and 
4.0-fold increases, respectively, for anti-H1N1 and almost 
4.0 (3.7) for patients and 5.3 for controls for anti-B Ab. 
Both groups presented a poor response against H3N2, 
with a <1.5-fold increase. Geometric median titres against 
each of the three virus strains are shown in table 1.
We found no significant differences in the proportion 
of patients who responded to the vaccine. (table 2).
Although not significant, there was a higher propor-
tion of healthy controls that achieved seroconversion 
against the influenza B virus. Thus, we calculated the 
sample size needed to identify possible significant differ-
ences between both cohorts. We found that it would be 
possible to identify differences, with better results in 
the control group, if a sample of 312 participants were 
enrolled (statistical power 80%, 95% CI). To include 
such a number of subjects, a multicenter study should 
be conducted that would confirm or not the different 
responses to the influenza B virus in healthy people and 
in patients on secukinumab.
In our study, secukinumab did not influence the 
response to the influenza vaccine (RR: 1.09 (95% CI 0.58 
to 2.07) for H1N1, RR: 1.53 (95% CI 0.15 to 15.0) for 
H3N2 and RR: 0.72 (95% CI 0.32 to 1.83) for B strain).
As far as we know, this is the first study published that 
investigates if secukinumab impairs the immunogenic 
response to the influenza vaccination in patients. Sero-
conversion rates were low but in line with the vaccine 
effectiveness rates reported for the 2017–2018 season.3 
Our results corroborate those communicated by Elkayam 
et al (available as abstract), who, during the 2017 season, 
found similar rates of seroprotection after the vaccine 
in patients with PsA treated with secukinumab and in 
healthy controls.4 Chioato et al described an immuno-
genic response of around 90% 4 weeks after the influ-
enza vaccination in healthy volunteers treated with 
secukinumab.5 Although seroconversion rates were lower 
in our series, neither study found worse responses in 
subjects taking secukinumab.
In summary, in our pilot study, we found that secuki-
numab has no effect on the immunogenic response to 
the influenza vaccine. Larger studies are needed to ratify 
this finding.
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